Start Your Journey To Wealth

It takes just a few minutes to register.

Your Money - Best Investment ISA - Large Portfolio 2024
Boring money - Best for Customer Service 2022
Broker Chooser - Best broker for funds 2022

ZIMMER BIOMET HOLDINGS INC COM STK USD0.01

Symbol: ZBH

This security went ex-dividend on 30/12/2025. Pay date is 30/01/2026

Whilst we endeavour to price investments on a real-time streaming or 15 min delayed basis, some prices may be as at close of business from the previous working day.

Invest in this share within an ISA, JISA, SIPP or Investment Account

Login Open an account

Overview

Core Data
Latest Dividend Information

Ex-Dividend Date Unknown
Pay Date Unknown
Total Dividends - Year to Date0
Dividend Yield (%)0

Historical Data & Ratios

Avg Volume Over 10 Days1.5399
Market Cap (M)18401.1600
Price/Earnings (PE)0
Earnings Per Share0
Revenue Per Share0
Return on Equity %0

1 Month Performance Chart

One Month Chart

Cost and Charges Information

This calculator provides you with costs and charges information regarding our charges and, where relevant, the costs within this investment product

Account Type

  • Investment Account
  • Stocks & Shares ISA
  • SIPP

Annual charges

These are the annual costs based on an initial investment amount of over 1 year assuming a net zero growth rate

Cost Category % of Investment lump sum costs
Our annual fee

Our annual fee

Includes our platform fee at 0.30% per annum (excluding Charles Stanley Multi Asset Funds and anycash held). The min fee is £60, the max is £600 per annum, plus SIPP administration fee (if applicable, only charged if < £30,000 held) – see here 		0.30%
Dealing charges

Dealing charges

Any one-off commission charges associated with investing. Note that government taxes and levies are not included. International equities incur additional costs including an International dealing rate that will be shown at the point of trade, as well as possible exchange costs when trading in overseas markets. This does not include any commission credits you may have available 		N/A
Product provider costs

Product provider costs

Product provider costs shown are inclusive of the fund ongoing charges figure (OCF), transaction costs and incidental costs 		N/A N/A
Total (£)

Total (£)

Costs per annum displayed in monetary value
Total (%)

Total (%)

Costs per annum displayed as a percentage of investment value

Cumulative effect of charges on your investment's return

This illustration assumes that costs occur evenly throughout the year, charges are paid out of the investment evenly throughout the year, and that an annual growth rate of applies evenly throughout the year, before any charges including product charges

lump sum invested with an assumed growth rate of 1 year years
What you might get back at  with no charges applied

What you might get back at  with no charges applied

These are the illustrative values of a  investment after growth and no costs applied at the end of the defined period
Annual charges

Annual charges

These are the annual costs based on an initial investment amount of assuming a net zero growth rate
Effect of charges on return (%)

Effect of charges on return (%)

These are the overall costs in percentage terms, based on an initial investment amount of assuming a growth rate
Effect of charges on return (£)

Effect of charges on return (£)

These are the overall costs in monetary value, based on an initial investment amount of assuming a growth rate
What you might get back at with charges applied

What you might get back at with charges applied

These are the illustrative values of a investment after growth and costs at the end of the defined period

This illustration is not a forecast of future investment performance but merely a means to demonstrate the potential impact of costs and charges for an assumed return of . Whilst we make reasonable endeavours to ensure the accuracy of third party charges information, this is intended for illustrative purposes only and should not be relied upon. We do not warrant or represent that this information is accurate, complete or up to date, therefore we accept no responsibility or liability for its use

Charts

  • Chart Options

    Select Timeframe Add a sector as a comparator Add an index as a comparator Add a share as a comparator

      Add a moving average as a comparator Add a lower indicator as a comparator Chart Style Current Comparators

      Company

      Business Summary

      Zimmer Biomet Holdings, Inc. is a global medical technology company. It designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; CMFT; surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. Its segments include Americas, EMEA, and Asia Pacific. Its products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Its knee brands include the Persona Knee, NexGen Knee Implants, Vanguard Knee and Oxford Partial Knee. Its hip brands include the Taperloc Hip System, Avenir Complete Hip System, Arcos Modular Hip System and G7 Acetabular System. It also focused on a suite of orthopedic robotics, enabling solutions and analytics to address the needs of surgeons pre-, intra- and post-operatively. Its portfolio features imageless robotics through its ROSA Robotics platform.

      Financial Summary

      BRIEF: For the nine months ended 30 September 2025, Zimmer Biomet Holdings Inc revenues increased 6% to $5.99B. Net income applicable to common stockholders decreased 15% to $565.7M. Revenues reflect Americas segment increase of 6% to $3.73B, EMEA segment increase of 6% to $1.33B, Asia Pacific segment increase of 5% to $928.7M, United States segment increase of 6% to $3.45B, International segment increase of 6% to $2.54B.

      Financials


      Income Statement - All values are in U.S. Dollars

      Year Ending

      31/12/2024

      31/12/2023

      31/12/2022

      31/12/2021

      31/12/2020

      31/12/2019

      Total Revenue 7,678.60 7,394.20 6,939.90 6,827.30 6,127.50 7,982.20
      Gross profit 5,487.40 5,310.40 4,920.40 4,866.90 4,303.20 5,729.60
      Operating Profit/Loss 1,285.70 1,277.70 696.30 695.20 83.10 1,137.50
      Profit Before Tax 1,036.60 1,067.30 403.50 499.00 -105.20 905.80
      Profit After Tax 905.20 1,025.10 291.20 445.50 -9.20 816.50
      Equity Holders of Parent Company 903.80 1,024.00 231.40 401.60 -138.90 1,131.60
      Minority Interest 6.60 6.60 5.70 5.20 3.70 4.80


      Balance Sheet - All values are in U.S. Dollars

      Year Ending

      31/12/2024

      31/12/2023

      31/12/2022

      31/12/2021

      31/12/2020

      31/12/2019

      Total Non-Current Assets 16,693.80 16,887.40 16,638.70 18,571.40 19,334.40 19,914.80
      Total Current Assets 4,671.50 4,609.50 4,427.30 4,885.00 5,083.30 4,723.90
      Total Assets 21,365.30 21,496.90 21,066.00 23,456.40 24,417.70 24,638.70
      Total Liabilities 8,889.10 9,008.80 9,039.00 10,790.00 12,218.30 12,245.90
      Total Net Assets 12,476.20 12,488.10 12,027.00 12,666.40 12,199.40 12,392.80
      Shareholders Funds 12,468.10 12,480.40 12,020.30 12,660.70 12,194.20 12,388.10
      Minority Interests 6.60 6.60 5.70 5.20 3.70 4.80
      Total Equity 12,476.20 12,488.10 12,027.00 12,666.40 12,199.40 12,392.80

      Outlook

      Sorry, broker view information on this investment is not available at this time.

      Time & Sales

      Sorry, sales information on this investment is not available at this time.

      Investment involves risk. You may get back less than invested.